

New Functionality Added to the “onti” Medical Isotope Exposure Dose Management System

**This release is an English translation of “医療被ばく線量管理システム「onti」に新機能を追加”, with a priority given to Japanese for content and interpretation. The indication is specifically for Japan only and not for other countries.*

TOKYO, JAPAN – March 17, 2025 - PDRadiopharma Inc. (President: Masato Murakami, Headquarters: Chuo-ku, Tokyo, “PDRadiopharma”) is pleased to announce the addition of a new functionality to its medical isotope exposure dose management system, “onti”. This new feature is designed to prevent errors in the administration of radiopharmaceutical and will be available starting March 31.

New Features “Label Printing Function”

- **Prevention of Entry Errors with Automated Label Printing**

By linking test details with patient data in “onti,” labels indicating test names and patient names for syringes used prior to administration can now be printed automatically. This eliminates handwriting errors and reduces operational workload.

- **Prevention of Labeling Mistakes**

Labels printed with patient-specific information ensure accurate labeling of the administered drugs, reducing the risk of mislabeling.

- **Improved Accuracy in Patient Verification**

In addition to visual confirmation of printed labels, a 2D barcode printed on the labels enables more accurate verification, further enhancing safety.

Beyond the supply of radiopharmaceuticals, we are committed to solving information management challenges by integrating data and digital technologies with medical DX solutions. We will continue to contribute to the advancement of safe and efficient radiopharmaceutical medicine while delivering higher-quality services.

About PDRadiopharma

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently PDRadiopharma offers 22 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan.

* “onti” is an information system that supports electronic recording, management, and optimization of radiation exposure. It has been sold by PDRadiopharma since October 2023.

Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit <https://www.pdradiopharma.com/>

Inquiries:

PDRadiopharma Inc.

Contact: Noriko Tanaka, General Affairs

Email: s-info-hq@pdradiopharma.com